ANI Pharmaceuticals Gains FDA Nod for Generic Everolimus Oral…

Event summary

ANI Pharmaceuticals received FDA approval for its generic Everolimus Tablets for Oral Suspension (2mg, 3mg, 5mg) on September 23, 2026.
The product is a generic version of Novartis' Afinitor Disperz®, with U.S. annual sales estimated at $123 million (July 2026 MAT).
ANI aims to launch at least 15 new generics this year, per CEO Nikhil Lalwani.
The approval strengthens ANI's U.S.-focused generics business, which has shown strong commercial momentum.

The big picture

ANI's FDA approval for Everolimus Tablets reinforces its strategy of leveraging R&D expertise in complex formulations to expand its generics portfolio. The move aligns with broader industry trends of increasing competition in the generic drug space, particularly for specialized oral suspensions. With a focus on U.S.-based manufacturing and commercialization, ANI is positioning itself to capitalize on high-value generic opportunities, though it must navigate regulatory and supply chain challenges.

What we're watching

Market Penetration: Whether ANI can capture significant market share from Afinitor Disperz® given the $123 million annual revenue opportunity.
Execution Risk: The pace at which ANI can commercialize its planned 15 generic launches this year.
Regulatory Dynamics: How FDA policy shifts may impact ANI's ability to bring limited-competition generics to market.